Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 11, 2026
TickeronGET DAILY SIGNALS
UnitedHealth Group (UNH) Q3 2026 Earnings: Key Metrics to Watch for Signs of Recovery

UnitedHealth Group (UNH) Q3 2026 Earnings: Key Metrics to Watch for Signs of Recovery

Key Takeaways

  • UnitedHealth Group (NYSE: UNH) reports its third quarter 2026 results on Tuesday, October 13, before the market opens.
  • Wall Street consensus points to earnings of roughly $4.12 per share on revenue near $111.5 billion.
  • The prior quarter marked a sharp recovery, with adjusted earnings per share (EPS) of $6.38 and a much-improved medical care ratio of 86.7%.
  • Investors will focus on the medical care ratio (MCR), Medicare Advantage enrollment, and momentum across the Optum businesses.
  • Management raised its full-year 2026 adjusted EPS guidance to $19.50–$20.00 in July, setting a high bar for the second half of the year.

Earnings Context and Why It Matters

UnitedHealth Group stands as the largest U.S. health insurer and a diversified healthcare services company, with operations spanning its UnitedHealthcare insurance arm and the Optum care, pharmacy, and technology platforms. After facing elevated medical costs throughout 2025, the company posted a notable rebound in the second quarter of 2026, where adjusted EPS rose more than 50% year over year alongside an improved medical care ratio. That performance, paired with the raised full-year guidance, has turned investor focus toward whether cost discipline and Optum’s growth trajectory can hold steady. This upcoming report serves as an important checkpoint on the recovery story and the firm’s capacity to protect profitability in its Medicare, Medicaid, and commercial lines.

Earnings Expectations

Analysts anticipate UnitedHealth will report third quarter 2026 revenue of about $111.5 billion, reflecting a modest year-over-year decline of roughly 1.5% from the $113.2 billion posted in the same period last year. Consensus earnings estimates stand near $4.12 per share, a level that marks a meaningful step up from the depressed results of a year earlier when higher medical costs pressured margins.

Several metrics will draw close attention. The medical care ratio remains the key figure for insurers, representing the portion of premium revenue paid out for medical care. In the second quarter, UNH posted an MCR of 86.7%, down from 89.4% a year earlier, although that reading included roughly $860 million of favorable prior-period reserve development. Management’s full-year 2026 guidance assumes an MCR of 88.1%, plus or minus 25 basis points, which suggests costs in the second half could run higher than in the first. Medicare Advantage enrollment trends, pressure on Medicaid margins, and growth across Optum Health, Optum Rx, and Optum Insight will also be scrutinized, along with any comments on the full-year adjusted EPS range of $19.50 to $20.00. I also checked this using Tickeron’s AI Screener to see how UNH stacks up against peers in the sector.

Market Reaction and Investor Sentiment

Sentiment ahead of the release appears cautiously optimistic yet unsettled. UNH stock has seen its forward price-to-earnings multiple compress over the past year as investors weighed medical cost inflation and regulatory concerns. The solid second-quarter results were well received, but management continues to highlight ongoing headwinds such as elevated commercial medical cost trends, Medicaid margin pressure, and lower Medicare Advantage enrollment. Options activity and analyst notes reflect a broad range of expectations, with emphasis on whether the MCR remains contained and whether Optum can sustain operating leverage. A report that confirms cost control and reaffirms guidance could lend support to the shares, whereas any indication of renewed cost pressure might revive doubts about the durability of the rebound.

Forward Outlook and Key Factors to Monitor

Beyond the third-quarter numbers, attention will turn to whether UnitedHealth can keep the medical care ratio near the upper end of its targeted band through year-end. Management has already signaled a back-half-weighted cost trend, making the fourth quarter an important test of that outlook.

Medicare Advantage enrollment will remain a focal point. The company has guided for a decline of roughly 1.1 million members in 2026 as it shifts the business toward margin improvement, and progress toward a Medicare margin above 3% will indicate whether that approach is succeeding. Medicaid profitability also warrants watching, given that state rate actions have lagged behind cost trends.

On the services side, Optum’s expansion—especially in care delivery, pharmacy services, and technology offerings—could help offset insurance-side pressures. Management has highlighted efficiency efforts, including reduced prior-authorization volume, which may support operating margins over time. Any update to full-year guidance or remarks on 2027 pricing will help shape views on the longer-term earnings path. From what I see, monitoring these elements closely will clarify how sustainable the current recovery appears.

Using AI Tools in My Research

One tool I find particularly useful for this kind of analysis is Tickeron’s AI Screener. It helps me quickly filter stocks and ETFs by technical patterns, fundamentals, trends, and AI-driven signals, which adds efficiency when preparing for earnings releases like this one. I can scan for comparable names in the healthcare space and spot potential trade ideas without spending hours on manual work. The platform serves as a practical complement to traditional research and has become a regular part of how I evaluate opportunities around events like UNH’s quarterly update.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: UNH

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


UNH's RSI Oscillator is staying in oversold zone for 2 days

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +1.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where UNH advanced for three days, in 187 of 331 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.

UNH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UNH as a result. In 56 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.

The Moving Average Convergence Divergence Histogram (MACD) for UNH turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 27 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 59%.

UNH moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for UNH crossed bearishly below the 50-day moving average on November 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where UNH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.

The Aroon Indicator for UNH entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. UNH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.594) is normal, around the industry mean (3.520). P/E Ratio (25.266) is within average values for comparable stocks, (126.353). Projected Growth (PEG Ratio) (1.025) is also within normal values, averaging (0.786). UNH has a moderately high Dividend Yield (0.024) as compared to the industry average of (0.009). P/S Ratio (0.757) is also within normal values, averaging (0.569).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UNH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

Notable companies

The most notable companies in this group are Unitedhealth Group (NYSE:UNH), CVS HEALTH Corp (NYSE:CVS), Elevance Health (NYSE:ELV), Cigna Group (The) (NYSE:CI), Humana (NYSE:HUM), Centene Corp (NYSE:CNC).

Industry description

Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.

Market Cap

The average market capitalization across the Managed Health Care Industry is 67.69B. The market cap for tickers in the group ranges from 335.99K to 353.79B. UNH holds the highest valuation in this group at 353.79B. The lowest valued company is IHGP at 335.99K.

High and low price notable news

The average weekly price growth across all stocks in the Managed Health Care Industry was -12%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was 1%. PGNY experienced the highest price growth at -1%, while CLOV experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the Managed Health Care Industry was 80%. For the same stocks of the Industry, the average monthly volume growth was 91% and the average quarterly volume growth was 67%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 44
Price Growth Rating: 54
SMR Rating: 72
Profit Risk Rating: 91
Seasonality Score: -6 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of hospital and medical service plans

Industry ManagedHealthCare

Industry
Managed Health Care
Address
1 Health Drive
Phone
+1 800 328-5979
Employees
390000
Web
https://www.unitedhealthgroup.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.